肝X受体激动剂在肿瘤治疗中的研究进展  

Advances in the inhibition of tumor growth by liver X receptor agonists

作　　者：吴文昊 李兴[1] WU Wenhao;LI Xing(Department of Endocrinology,the Second Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China)

机构地区：[1]山西医科大学第二临床医学院内分泌科,山西太原030001

出　　处：《现代肿瘤医学》2022年第21期4022-4026,共5页Journal of Modern Oncology

摘　　要：肝X受体(liver X receptors,LXRs)是孤儿核受体转录因子超家族成员,当LXRs被激活后,可调节靶基因的转录表达,不但参与胆固醇、脂肪、糖的代谢以及炎症等过程,并且在许多恶性肿瘤组织中均有表达。为全面了解肝X受体激动剂在治疗癌症中的研究现状,本文将从肝X受体激动剂与胃癌、肝癌、卵巢癌、乳腺癌、子宫内膜癌、肺癌以及结直肠癌的相关性方面进行综述。Liver X receptors(LXRs)are members of the superfamily of orphan nuclear receptor transcription factors.When activated,LXRs can regulate the transcriptional expression of target genes,which are not only involved in the metabolism of cholesterol,fat,sugar and inflammation,but also expressed in many malignant tumor tissues.In order to comprehensively understand the research status of liver X receptor agonist in the treatment of cancer,this paper will review the correlation between liver X receptor agonist and stomach,liver,ovarian,breast,endometrial,lung,and colorectal cancer.

关 键 词：肝X受体 肝X受体激动剂 肿瘤 治疗 

分 类 号：R735.7[医药卫生—肿瘤]